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Pseudomonas aeruginosa biofilms are involved in several infectious 
diseases and their eradication remains a challenge. Disrupting the 
biofilm matrix is the most attractive way to facilitate biofilm-cells 
eradication and glutathione has been exhibiting great potential as a 
biofilm disrupter agent. Therefore, this study aimed to explore anti-
biofilm strategies based on the combination of glutathione with two 
in-use antibiotics. Biofilms were formed and subjected to the action of 
combinatorial arrangements of glutathione with ciprofloxacin or 
tobramycin. Preliminary results showed that PAO1 biofilms were 
eradicated using glutathione+ciprofloxacin, in contrast to biofilms 
formed by a clinical isolate (PAI). Better outcomes were obtained 
using glutathione+tobramycin since biomass reduction occurred with 
lower dosages. Also, a different action than the usually described for 
glutathione is suggested. In conclusion, glutathione-tobramycin could 
be a potential anti-biofilm strategy. 
 
 
 
 
P. aeruginosa is a gram-negative, ubiquitous environmental 
bacterium frequently found in diverse environments such as 
water, soil and plants in the form of biofilms. Biofilms are 
defined as highly structured, surface-attached communities of 
cells encased within a self-produced extracellular polymeric 
matrix forming a shell around a microbial community conferring 
to the microorganisms a protective environment [1]. P. 
aeruginosa biofilms have been linked to several human 
infectious diseases, such as nosocomial infections and cystic 
fibrosis, and to medical equipment  [2–4]. The eradication of 
these biofilms poses several challenges because the 
antimicrobial resistance of biofilms is multifactorial resulting 
from the combination of different mechanisms, including 
restricted penetration of antimicrobials through the 
exopolysaccharide matrix, slow growth of bacteria within 
biofilms and cell-to-cell communication systems [5]. 
Attempting to eradicate P. aeruginosa biofilms, several 
treatments have been used but, unfortunately, P. aeruginosa 
infections still persist. Therefore, new strategies to eradicate P. 
aeruginosa biofilms are required. Biofilm matrix disruption has 
been considered an attractive approach because it can expose 
biofilm-cells to the action of antimicrobial agents. Typically, P. 
aeruginosa biofilm matrix contains a lot of compounds 
including significant amounts of pyocyanin, a blue redox-active 
phenazine that confers structural integrity to the biofilm, and 
extracellular DNA (eDNA) [6,7]. Glutathione is an human 
antioxidant that reacts with pyocyanin and eDNA intercalation 
being thus proposed as a potential matrix disruptor agent [7–9]. 
We hypothesized that combined with antibiotics, glutathione 
could weaken biofilms affecting the biofilm integrity and so 
augmenting the efficacy of the antimicrobial agents using 
reduced concentrations. Therefore, this study aimed to 
determine the anti-biofilm potential of glutathione in the 
disruption of biofilm matrix and to develop anti-biofilm 
strategies based on a possible synergistic effect resulting from 
combining glutathione with two different antibiotics, 
ciprofloxacin and tobramycin.  
In this study, two P. aeruginosa strains were used, a laboratory 
strain PAO1, antibiotic sensitive and non-pyocyanin producer, 
and a clinical isolate PAI, antibiotic resistant and pyocyanin 
producer in order to reflect some of the P. aeruginosa biofilms 
diversity found in the hospital and industrial settings.  
Biofilms were formed on a 96-well microtitre plate for 24, 48 
and 72 h to obtain different biofilm ages (immature and mature 
biofilms). Briefly, 200 µL per well of 1x107 CFU/mL overnight 
bacterial suspensions prepared in TSB were transferred into a 
96-well microtitre plate and incubated aerobically at 37 °C under 
agitation (120 rpm). After biofilm formation, the content of the 
wells was discarded and biofilms washed to remove weakly 
attached cells and further treated with the combinatorial 
strategies. Checkerboard arrangements of glutathione, ranging 
from 1 to 8 mM, with ciprofloxacin, ranging from 1 to 32 
µg/mL, or tobramycin ranging from 1 to 64 µg/mL were 
performed to determine the most effective anti-biofilm strategy. 
All these dual-arrangements were in contact with biofilms for 24 
h. Biofilm biomass (determined by crystal violet assay [10]) and 
viable cells counting were determined before and after the 
application of the antimicrobial strategies to evaluate their anti-
biofilm efficacy.  
The preliminary results showed that the efficacy of the anti-
biofilm approach of glutathione+ciprofloxacin reduced as the 
biofilm became more mature, since 24 h-old-biofilms were more 
susceptible than 48 h- and 72 h-old-biofilms. To augment anti-
biofilm efficacy, increased concentrations of ciprofloxacin were 
needed and, even so, eradication did not occur for the two P. 
aeruginosa biofilms. The antibiotic susceptibility of P. 
aeruginosa strains seemed to have a great impact on the efficacy 
of this anti-biofilm strategy since all PAO1 biofilms suffered 
biomass reduction or were eradicated using 
glutathione+ciprofloxacin, in contrast to PAI biofilms in which 
no effect was observed. This result may be explained by the 
ciprofloxacin tolerance of PAI.  
Interestingly, it was verified that glutathione+ciprofloxacin 
combination seemed to have action over PAO1 biofilms where 
there is no pyocyanin within the matrix. This finding led us to 
speculate that glutathione may not only act over pyocyanin and 
eDNA intercalation. 
The combination glutathione+tobramycin exhibited improved 
preliminary results; although the same loss of efficacy was 
observed as biofilms became more mature. PAO1 biofilms were 
eradicated using low concentrations of glutathione and 
tobramycin, 1.5 mM and 16 µg/mL, respectively. The increased 
susceptibility of PAO1 biofilms to this last combination, 
reinforced our assumption that glutathione may play another role 
in biofilm matrix disruption. Young 24 h-old PAI biofilms were 
load reduced using low dosages of glutathione and 
tobramycin,1.5 mM and 32 µg/mL respectively. However, 
mature PAI biofilms with 48 h and 72 h of growth were again 
more tolerant to glutathione and tobramycin combination and 
increased concentrations of glutathione and tobramycin, 2 mM 
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and 64 µg/mL, respectively were needed to obtain a significant 
load reduction of biofilm cells and biomass.  
Moreover, it was also observed that glutathione, ciprofloxacin 
and tobramycin did not exhibit increased or equal efficacy 
against P. aeruginosa biofilms when applied alone highlighting 
the beneficial result of co-applying different kind of agents to 
eradicate biofilms. 
In conclusion, the combination of glutathione with tobramycin 
could be a potential anti-biofilm strategy to be applied in clinical 
biofilms. This finding was quite relevant to continue exploring 
other biotechnological solutions based on the synergistic effect 
between antimicrobials and glutathione to eradicate P. 
aeruginosa biofilms. 
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